GoodRx Holdings, Inc. (GDRX) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GoodRx Holdings, Inc. (GDRX), Healthcare sektöründe faaliyet gösteriyor, son olarak 2.83$'dan işlem görüyor ve 960405766 piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 56/100 puan alıyor.
Son analiz: 9 Şub 2026GoodRx Holdings, Inc. (GDRX) Sağlık ve Boru Hattı Genel Bakışı
GoodRx Holdings, Inc. empowers consumers to make informed healthcare decisions by providing transparent prescription drug pricing and access to discounts, leveraging its extensive network and innovative platform to drive affordability and accessibility in the pharmaceutical market.
Yatırım Tezi
GoodRx presents a notable research candidate due to its established market position and potential for continued growth in the healthcare information services sector. With a P/E ratio of 26.73 and a gross margin of 91.0%, the company demonstrates strong profitability and operational efficiency. The increasing demand for affordable healthcare solutions and prescription drug price transparency should drive user growth and subscription revenue. Key catalysts include the expansion of telehealth services and partnerships with pharmaceutical manufacturers. The company's beta of 1.50 suggests higher volatility than the market. The ongoing focus on innovation and strategic acquisitions could further solidify GoodRx's market leadership and enhance shareholder value.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.83B indicates a significant, yet still scalable, presence in the healthcare information services market.
- P/E ratio of 26.73 suggests investors are paying a premium for current earnings, reflecting expectations of future growth.
- Gross Margin of 91.0% highlights the company's efficient business model and strong pricing power.
- Profit Margin of 4.0% demonstrates the company's ability to convert revenue into profit, with potential for further improvement through operational efficiencies.
- Beta of 1.50 indicates the stock is more volatile than the market, potentially offering higher returns but also greater risk.
Rakipler & Benzerleri
Güçlü Yönler
- Strong brand recognition and user base.
- Extensive network of pharmacy partnerships.
- Proprietary technology platform.
- High gross margins.
Zayıflıklar
- Reliance on pharmacy partnerships.
- Competition from other price comparison platforms.
- Potential regulatory changes affecting the pharmaceutical industry.
- Relatively low profit margin.
Katalizörler
- Ongoing: Expansion of telehealth services to increase revenue streams.
- Ongoing: Partnerships with pharmaceutical manufacturers to improve medication adherence and offer discounts.
- Ongoing: Growth of subscription-based offerings to drive recurring revenue.
- Upcoming: Potential acquisitions of complementary businesses to expand service offerings.
Riskler
- Potential: Increased competition from other price comparison platforms.
- Potential: Changes in pharmacy benefit manager (PBM) practices affecting revenue.
- Ongoing: Regulatory scrutiny of prescription drug pricing impacting business model.
- Potential: Economic downturn affecting consumer spending on healthcare.
- Ongoing: Reliance on maintaining strong relationships with pharmacy partners.
Büyüme Fırsatları
- Expansion of Telehealth Services: GoodRx can leverage its existing user base to expand its telehealth offerings, providing convenient access to healthcare professionals and generating additional revenue streams. The telehealth market is projected to reach $278.5 billion by 2030, presenting a significant growth opportunity for GoodRx. By integrating telehealth services into its platform, GoodRx can enhance its value proposition and attract new users.
- Partnerships with Pharmaceutical Manufacturers: Collaborating with pharmaceutical manufacturers to offer discounts and improve medication adherence can drive revenue growth and strengthen GoodRx's position in the market. Pharma manufacturer solutions represent a significant growth area, allowing GoodRx to leverage its platform to connect manufacturers with patients and improve health outcomes. These partnerships can also provide GoodRx with exclusive access to discounts and promotions, further enhancing its value proposition.
- Subscription Model Expansion: Growing the subscription-based offerings, such as GoodRx Gold, can provide recurring revenue and increase customer loyalty. Subscriptions offer deeper discounts and additional benefits, attracting frequent users and driving long-term value. By expanding its subscription model, GoodRx can create a more predictable revenue stream and strengthen its relationship with its most valuable customers.
- Geographic Expansion: While primarily focused on the United States, GoodRx could explore opportunities to expand its services to other countries with similar healthcare challenges. International expansion could significantly increase GoodRx's addressable market and drive long-term growth. However, it would also require navigating different regulatory environments and healthcare systems.
- Data Analytics and Personalization: Leveraging data analytics to personalize the user experience and provide targeted recommendations can improve engagement and drive revenue growth. By analyzing user data, GoodRx can identify individual needs and preferences, providing tailored discounts and healthcare solutions. This personalized approach can enhance user satisfaction and increase the likelihood of repeat usage.
Fırsatlar
- Expansion of telehealth services.
- Partnerships with pharmaceutical manufacturers.
- Growth of subscription-based offerings.
- Geographic expansion.
Tehditler
- Increased competition from established players and new entrants.
- Changes in pharmacy benefit manager (PBM) practices.
- Regulatory scrutiny of prescription drug pricing.
- Economic downturn affecting consumer spending on healthcare.
Rekabet Avantajları
- Brand recognition and trust among consumers.
- Extensive network of pharmacy partnerships.
- Proprietary technology platform for price comparison.
- Large user base and data analytics capabilities.
GDRX Hakkında
GoodRx Holdings, Inc., founded in 2015 and headquartered in Santa Monica, California, has rapidly become a pivotal player in the healthcare information services sector. The company's core offering is a price comparison platform that allows consumers to compare prescription drug prices across various pharmacies in the United States. This platform provides geographically relevant pricing information and access to negotiated prices through GoodRx codes, enabling users to save money on their prescriptions. Beyond its price comparison tool, GoodRx has expanded its services to include subscriptions, offering deeper discounts and additional benefits to frequent users. The company also provides pharma manufacturer solutions, helping pharmaceutical companies connect with patients and improve medication adherence. Further diversifying its offerings, GoodRx has ventured into telehealth services, providing convenient access to healthcare professionals. By serving both consumers and pharmacy benefit managers, GoodRx facilitates transparency and efficiency in prescription drug transactions, establishing itself as a key intermediary in the pharmaceutical ecosystem.
Ne Yaparlar
- Provide a price comparison platform for prescription drugs.
- Offer geographically relevant prescription pricing information.
- Provide access to negotiated prices through GoodRx codes.
- Offer subscription services for deeper discounts.
- Provide telehealth services for convenient access to healthcare professionals.
- Offer pharma manufacturer solutions to connect pharmaceutical companies with patients.
- Serve pharmacy benefit managers to facilitate prescription transactions.
İş Modeli
- Generate revenue through advertising and partnerships with pharmacies.
- Earn subscription fees from GoodRx Gold and other subscription services.
- Receive fees from pharmaceutical manufacturers for connecting them with patients.
- Generate revenue from telehealth services.
Sektör Bağlamı
GoodRx operates within the rapidly evolving healthcare information services industry, driven by increasing consumer demand for transparency and affordability in prescription drug pricing. The market is characterized by a complex web of pharmacy benefit managers, pharmaceutical manufacturers, and pharmacies, creating opportunities for intermediaries like GoodRx to streamline the process and provide value to consumers. The industry is experiencing growth due to rising healthcare costs and the increasing adoption of digital health solutions. Competitors like AHCO, AMPH, COLL, CTEV, and HSTM are vying for market share, but GoodRx's established brand and extensive network provide a competitive edge.
Kilit Müşteriler
- Consumers seeking affordable prescription drugs.
- Pharmacy benefit managers (PBMs).
- Pharmaceutical manufacturers.
- Pharmacies.
Finansallar
Grafik & Bilgi
GoodRx Holdings, Inc. (GDRX) hisse senedi fiyatı: $2.83 (+0.08, +2.91%)
Son Haberler
-
How The Reset In Expectations Is Reframing The GoodRx Holdings (GDRX) Investment Story
Yahoo! Finance: GDRX News · 25 Mar 2026
-
1 Value Stock with Exciting Potential and 2 Facing Challenges
Yahoo! Finance: GDRX News · 24 Mar 2026
-
GoodRx (NASDAQ:GDRX) versus Biocorrx (OTCMKTS:BICX) Critical Comparison
defenseworld.net · 23 Mar 2026
-
HIMS Expands Personalized Digital Healthcare Access and Services
Yahoo! Finance: GDRX News · 16 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GDRX için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GDRX için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GDRX'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
How The Reset In Expectations Is Reframing The GoodRx Holdings (GDRX) Investment Story
1 Value Stock with Exciting Potential and 2 Facing Challenges
GoodRx (NASDAQ:GDRX) versus Biocorrx (OTCMKTS:BICX) Critical Comparison
HIMS Expands Personalized Digital Healthcare Access and Services
GoodRx Holdings, Inc. Hissesi: Cevaplanan Temel Sorular
GDRX için değerlendirilmesi gereken temel faktörler nelerdir?
GoodRx Holdings, Inc. (GDRX) şu anda yapay zeka skoru 56/100, orta puanı gösteriyor. Temel güçlü yan: Strong brand recognition and user base.. İzlenmesi gereken birincil risk: Potential: Increased competition from other price comparison platforms.. Bu bir finansal tavsiye değildir.
GDRX MoonshotScore'u nedir?
GDRX şu anda MoonshotScore'da 56/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GDRX verileri ne sıklıkla güncellenir?
GDRX fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GDRX hakkında ne diyor?
GDRX için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GDRX'a yatırım yapmanın riskleri nelerdir?
GDRX için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increased competition from other price comparison platforms.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GDRX'ın P/E oranı nedir?
GDRX için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GDRX'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GDRX aşırı değerli mi, yoksa düşük değerli mi?
GoodRx Holdings, Inc. (GDRX)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GDRX'ın temettü verimi nedir?
GoodRx Holdings, Inc. (GDRX) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- Forward-looking statements are subject to risks and uncertainties.